A recent study [45] confirmed the above-reported findings [44, 46, 47] identifying EZH2, MYD88, CREBBP, MLL2, MEF2B, and CD58, in addition to several other genes, as targets of recurrent mutation in DLBCL [45]. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.